Cardiol Therapeutics



Cardiol Therapeutics is a clinical stage drug development company with focused on the development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. They are pioneering the use of organic chemistry to produce cannabidiol without ever touching the plant. This patented formulation, called CardiolRx, extends the shelf life of the drug from 90 days to over two years and is being produced at scale in a cGMP lab. Cardiol is currently conducting Phase 2 clinical trials for two indications: Acute Myocaridtis and Recurrent Pericarditis, both of which offer a billion dollar opportunity for which the company is expecting to receive Orphan Drug status. They are also developing a subcutaneous treatment for heart failure which represents a $20B market opportunity. Cardiol’s advisors and trial partners include a who’s who in the industry with leading cardiac physicians from Mayo Clinic, Cleveland Clinic, Brigham and Women’s Hospital, Tel Aviv Medical Center and many others.


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.